These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38616443)

  • 61. Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer.
    Denduluri N; Miller K; O'Regan RM
    Am Soc Clin Oncol Educ Book; 2018 May; 38():47-55. PubMed ID: 30231324
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
    O'Sullivan CC; Ballman KV; McCall L; Kommalapati A; Zemla T; Weiss A; Mitchell M; Blinder V; Tung NM; Irvin WJ; Lee M; Goetz MP; Symmans WF; Borges VF; Krop I; Carey LA; Partridge AH
    Future Oncol; 2021 Dec; 17(34):4665-4676. PubMed ID: 34636255
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

  • 65. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
    Okines AF
    Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
    Chen XS; Yuan Y; Garfield DH; Wu JY; Huang O; Shen KW
    PLoS One; 2014; 9(9):e108405. PubMed ID: 25247558
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Additional value of
    van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT
    Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Outcomes in patients with small node-negative invasive breast cancer.
    Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
    Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neoadjuvant treatment of breast cancer--Clinical and research perspective.
    Loibl S; Denkert C; von Minckwitz G
    Breast; 2015 Nov; 24 Suppl 2():S73-7. PubMed ID: 26387601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
    Whitehead I; Irwin GW; Bannon F; Coles CE; Copson E; Cutress RI; Dave RV; Gardiner MD; Grayson M; Holcombe C; Irshad S; O'Brien C; O'Connell RL; Palmieri C; Shaaban AM; Sharma N; Singh JK; Potter S; McIntosh SA;
    BMC Cancer; 2021 Jan; 21(1):90. PubMed ID: 33482770
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
    Weiss A; Campbell J; Ballman KV; Sikov WM; Carey LA; Hwang ES; Poppe MM; Partridge AH; Ollila DW; Golshan M
    Ann Surg Oncol; 2021 Oct; 28(11):5960-5971. PubMed ID: 33821344
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
    Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis.
    Murchison S; Nichol A; Speers C; Gondara L; Levasseur N; Lohrisch C; Vallieres I; Truong P
    Clin Breast Cancer; 2022 Oct; 22(7):e773-e787. PubMed ID: 35915021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.